Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice

[1]  M. Xie,et al.  Immunomodulatory Activity of Ganoderma atrum Polysaccharide on Purified T Lymphocytes through Ca2+/CaN and Mitogen-Activated Protein Kinase Pathway Based on RNA Sequencing. , 2017, Journal of agricultural and food chemistry.

[2]  T. Anagnostou,et al.  The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation , 2016, Front. Immunol..

[3]  Yun Yang,et al.  Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer. , 2016, Biochemical and biophysical research communications.

[4]  H. Gogas,et al.  Melanoma immunotherapy dominates the field. , 2016, Annals of translational medicine.

[5]  V. Gotlieb,et al.  The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. , 2016, Critical reviews in oncology/hematology.

[6]  Matteo Brunelli,et al.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.

[7]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[8]  G. Freeman,et al.  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. , 2015, Clinical therapeutics.

[9]  A. Ribas,et al.  The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? , 2015, Current opinion in immunology.

[10]  Martin F. Mihm,et al.  Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 , 2013, Journal of Translational Medicine.

[11]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[12]  F. Marincola,et al.  Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” , 2013, Journal of Translational Medicine.

[13]  N. Popitsch,et al.  CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.

[14]  G. Freeman,et al.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.

[15]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[16]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[17]  Hui Wang,et al.  Effective inhibition of a Strongylocentrotus nudus eggs polysaccharide against hepatocellular carcinoma is mediated via immunoregulation in vivo. , 2011, Immunology letters.

[18]  Hui Wang,et al.  A polysaccharide from Strongylocentrotus nudus eggs protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice. , 2011, International immunopharmacology.

[19]  C. Liu,et al.  Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. , 2010, Cellular and molecular biology.

[20]  Hong-xiang Sun,et al.  Antitumor and immunomodulatory activity of polysaccharides from the roots of Actinidia eriantha. , 2009, Journal of ethnopharmacology.

[21]  Tao Xi,et al.  Immunomodulatory activity of polysaccharides isolated from Strongylocentrotus nudus eggs. , 2008, International immunopharmacology.

[22]  Tao Xi,et al.  Characterization and antitumor activity of a polysaccharide from Strongylocentrotus nudus eggs , 2007 .

[23]  M. Quinn,et al.  Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. , 2006, International immunopharmacology.

[24]  Catherine M Sherwin,et al.  Acute Lipopolysaccharide-Mediated Injury in Neonatal White Matter Glia: Role of TNF-α, IL-1β, and Calcium1 , 2005, The Journal of Immunology.

[25]  Catherine M Sherwin,et al.  Acute lipopolysaccharide-mediated injury in neonatal white matter glia: role of TNF-alpha, IL-1beta, and calcium. , 2005, Journal of immunology.

[26]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[27]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.